CM
ORGO icon

Crestline Management’s Organogenesis Holdings ORGO Stock Holding History

Crestline Management’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-156,279
Closed -$1.44M – 311
2021
Q4 		$1.44M Sell
156,279
-23,803
-13% -$253K 0.11% 126
2021
Q3 		$2.56M Buy
+180,082
New +$2.8M 0.24% 94

Other funds holding ORGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Crestline Management's ORGO Position: Q1 2022 in Review

Crestline Management sold out of Organogenesis Holdings (ORGO) in Q1 2022, closing a stake of 156,279 shares — an estimated $1.44M sold.

Crestline Management first reported a position in ORGO in Q3 2021 and held it in 2 quarters. The position peaked at $2.56M in Q3 2021. 156 funds tracked by Wall St. Rank hold ORGO as of Q1 2022.

  • Crestline Management reported no remaining Organogenesis Holdings position as of Q1 2022 after selling out during the quarter.
  • Crestline Management sold 156,279 Organogenesis Holdings shares in Q1 2022, an estimated $1.44M.
  • Crestline Management first reported a position in Organogenesis Holdings in Q3 2021 and held it in 2 quarters.
  • Crestline Management's Organogenesis Holdings position peaked at $2.56M in Q3 2021.
  • 156 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2022.

Based on Crestline Management's 13F filing for Q1 2022, filed 16 May 2022.